Literature DB >> 26925448

Expression and purification of virus like particles (VLPs) of foot-and-mouth disease virus in Eri silkworm (Samia cynthia ricini) larvae.

Manoj Kumar1, P Saravanan1, S K Jalali2.   

Abstract

Foot-and-mouth disease (FMD) is a highly contagious viral disease, which causes severe economic loss to livestock. Virus like particles (VLPs) produced by recombinant DNA technology are gaining importance because of their immunogenic properties and safety in developing a new vaccine for FMD. In the present study, a practical and economically feasible approach of expression, purification and characterization of VLPs of FMDV in Eri silkworm (Samia cynthia ricini) larvae was described. Although three lepidopteran insect larvae (Helicoverpa armigera, Spodoptera litura and Samia cynthia ricini) were tested for production of VLPs, expression was obtained only in Eri silkworm larvae. High titred recombinant baculovirus encoding the polyprotein P1-2A-3C of FMDV was prepared in Sf9 cells. Injection of recombinant baculovirus into hemocoel of Eri silkworm larvae resulted in increasing levels of expression of VLPs in the hemolymph from 3 to 7 days post infection (dpi) compared to low level expression by oral feeding. The VLPs reacted in Sandwich ELISA with serum raised against whole virus particles of FMDV type O/IND/R2/75 and protein banding pattern of 26, 37 and 47 kDa in Western blotting demonstrated their antigenic resemblance to native virus. Sucrose density gradient purified VLPs were used for immunization of rabbits and guinea pigs for assessing immunogenicity. Further, the reactivity of serum samples of rabbits and guinea pigs in Indirect-ELISA with titres (1.30-2.81 Log10) indicated that the VLPs were antigenic and immunogenic in nature. We demonstrate that Eri silkworm larvae could be used for production of VLPs of FMDV type O/IND/R2/75 for the first time. This approach could be useful for large scale production of recombinant VLPs for vaccine or diagnostic use in FMD control programme.

Entities:  

Keywords:  Baculovirus expression; Eri silkworm larva; FMDV; Hemolymph; Purification of VLPs; Virus like particles (VLPs)

Year:  2015        PMID: 26925448      PMCID: PMC4758304          DOI: 10.1007/s13337-015-0290-8

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  17 in total

1.  The large-scale production of an artificial influenza virus-like particle vaccine in silkworm pupae.

Authors:  Kuniaki Nerome; Shigeo Sugita; Kazumichi Kuroda; Toshiharu Hirose; Sayaka Matsuda; Kei Majima; Kazunori Kawasaki; Toshikatsu Shibata; Okti Nadia Poetri; Retno D Soejoedono; Ni L P Ika Mayasari; Srihadi Agungpriyono; Reiko Nerome
Journal:  Vaccine       Date:  2014-11-18       Impact factor: 3.641

2.  Recombinant hepatitis C virus-like particles expressed by baculovirus: utility in cell-binding and antibody detection assays.

Authors:  Jinhua Xiang; Sabina Wünschmann; Sarah L George; Donna Klinzman; Warren N Schmidt; Douglas R LaBrecque; Jack T Stapleton
Journal:  J Med Virol       Date:  2002-12       Impact factor: 2.327

3.  Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris.

Authors:  Janis Freivalds; Andris Dislers; Velta Ose; Paul Pumpens; Kaspars Tars; Andris Kazaks
Journal:  Protein Expr Purif       Date:  2010-09-18       Impact factor: 1.650

4.  FMD subunit vaccine produced using a silkworm-baculovirus expression system: protective efficacy against two type Asia1 isolates in cattle.

Authors:  Zhiyong Li; Xiangping Yin; Yongzhu Yi; Xuerui Li; Baoyu Li; Xi Lan; Zhifang Zhang; Jixing Liu
Journal:  Vet Microbiol       Date:  2010-11-04       Impact factor: 3.293

5.  Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography.

Authors:  Jin-Oh Baek; Jeong-Woo Seo; Ik-Hwan Kim; Chul Ho Kim
Journal:  Protein Expr Purif       Date:  2010-08-15       Impact factor: 1.650

6.  Incursions of foot-and-mouth disease virus into Europe between 1985 and 2006.

Authors:  J-F Valarcher; Y Leforban; M Rweyemamu; P L Roeder; G Gerbier; D K J Mackay; K J Sumption; D J Paton; N J Knowles
Journal:  Transbound Emerg Dis       Date:  2008       Impact factor: 5.005

Review 7.  Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Authors:  Natasha Kushnir; Stephen J Streatfield; Vidadi Yusibov
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

8.  Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli.

Authors:  Chien-Der Lee; Yao-Pei Yan; Shu-Mei Liang; Ting-Fang Wang
Journal:  J Biomed Sci       Date:  2009-08-11       Impact factor: 8.410

9.  Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine.

Authors:  Zhiyong Li; Yongzhu Yi; Xiangping Yin; Zhifang Zhang; Jixing Liu
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

10.  Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs.

Authors:  Yimei Cao; Zengjun Lu; Jiachuan Sun; Xingwen Bai; Pu Sun; Huifang Bao; Yingli Chen; Jianhong Guo; Dong Li; Xiangtao Liu; Zaixin Liu
Journal:  Vet Microbiol       Date:  2008-12-11       Impact factor: 3.293

View more
  2 in total

Review 1.  Antimicrobial Resistance: Its Surveillance, Impact, and Alternative Management Strategies in Dairy Animals.

Authors:  Chetan Sharma; Namita Rokana; Mudit Chandra; Brij Pal Singh; Rohini Devidas Gulhane; Jatinder Paul Singh Gill; Pallab Ray; Anil Kumar Puniya; Harsh Panwar
Journal:  Front Vet Sci       Date:  2018-01-08

Review 2.  Foot-and-Mouth Disease Virus: Immunobiology, Advances in Vaccines and Vaccination Strategies Addressing Vaccine Failures-An Indian Perspective.

Authors:  Raj Kumar Singh; Gaurav Kumar Sharma; Sonalika Mahajan; Kuldeep Dhama; Suresh H Basagoudanavar; Madhusudan Hosamani; B P Sreenivasa; Wanpen Chaicumpa; Vivek Kumar Gupta; Aniket Sanyal
Journal:  Vaccines (Basel)       Date:  2019-08-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.